BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 2669082)

  • 21. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
    Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
    Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
    Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
    Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
    Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
    Zehnder C; Blumberg A
    Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Iron stores in patients with chronic kidney failure treated with recombinant human erythropoietin].
    Cermák J; Gregora E; Lachmanová J; Brabec V
    Vnitr Lek; 1994 Mar; 40(3):174-8. PubMed ID: 8184571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epoetin: human recombinant erythropoietin.
    Flaharty KK; Grimm AM; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
    Roger SD; Baker LR; Raine AE
    Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron metabolism and iron substitution during erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Erythropoietin, a milestone in the history of nephrology].
    Uehlinger DE; Frey FJ
    Ther Umsch; 1995 Oct; 52(10):672-7. PubMed ID: 7482378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron status in patients receiving erythropoietin for dialysis-associated anemia.
    Van Wyck DB; Stivelman JC; Ruiz J; Kirlin LF; Katz MA; Ogden DA
    Kidney Int; 1989 Feb; 35(2):712-6. PubMed ID: 2709674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.